➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Colorcon
Merck
McKinsey
Mallinckrodt

Last Updated: March 8, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TINIDAZOLE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Tinidazole

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003617 Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach Unknown status Lymphoma Trials Office Phase 3 1995-03-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known whether chlorambucil is more effective than observation in treating low-grade lymphoma of the stomach. PURPOSE: Randomized phase III trial to compare the effectiveness of chlorambucil with that of no further therapy following anti-Helicobacter therapy in treating patients with low-grade lymphoma of the stomach.
NCT00132171 Helicobacter Pylori Eradication With a New Sequential Treatment Completed St. Orsola Hospital Phase 3 2001-01-01 Eradication rates of Helicobacter pylori (H. pylori) with standard triple therapy are disappointing, and studies from several countries confirm this poor performance. The study aimed to assess the eradication rate of a new sequential treatment regimen compared with conventional triple therapy for the eradication of H. pylori infection.
NCT00229216 Treatment of Bacterial Vaginosis With Oral Tinidazole Completed Mission Pharmacal Phase 3 2005-01-01 The purpose of this study is to confirm the safety and efficacy of oral tinidazole for the treatment of bacterial vaginosis.
NCT00313131 Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments Completed Canadian International Development Agency Phase 3 2004-01-01 This randomised controlled trial aimed to verify whether directly observed single dose treatment (with tinidazole+fluconazole) would be as effective as the longer standard treatments (metronidazole for 7 days, plus vaginal clotrimazole for 3 days) in the syndromic management of women presenting with vaginal discharge in primary health care centers of Ghana, Togo, Guinea and Mali. It was designed as an effectiveness trial, i.e. it was done under conditions typical of routine work in these health centers
NCT00313131 Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments Completed Université de Sherbrooke Phase 3 2004-01-01 This randomised controlled trial aimed to verify whether directly observed single dose treatment (with tinidazole+fluconazole) would be as effective as the longer standard treatments (metronidazole for 7 days, plus vaginal clotrimazole for 3 days) in the syndromic management of women presenting with vaginal discharge in primary health care centers of Ghana, Togo, Guinea and Mali. It was designed as an effectiveness trial, i.e. it was done under conditions typical of routine work in these health centers
NCT00322465 NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole) Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 2006-11-01 This study will look at the safety, effectiveness, and tolerability of combination medications for the initial treatment of non-gonococcal urethritis (NGU). NGU is inflammation of the tube that carries urine from the bladder. NGU is caused by bacteria that may be passed from person to person during sex. This study will compare the 2 currently recommended NGU treatments, doxycycline and azithromycin, taken with tinidazole (another medication to treat certain sexually transmitted infections). Tinidazole used with doxycycline or azithromycin may cure NGU better than when doxycycline or azithromycin is used alone. Study participants will be 300 men ages 16-45 years with NGU attending sexually transmitted disease clinics in Birmingham, AL; New Orleans, LA; Durham, NC; and Baltimore, MD. Study participation will last 7 weeks and involve 3 visits. At each visit, participants will provide a urine sample, have 2 urethral swabs, and have their urethra checked for discharge indicating infection.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tinidazole

Condition Name

Condition Name for Tinidazole
Intervention Trials
Helicobacter Pylori Infection 12
Bacterial Vaginosis 5
Helicobacter Infections 2
H. Pylori Infection 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tinidazole
Intervention Trials
Helicobacter Infections 10
Infection 8
Vaginosis, Bacterial 6
Vaginal Diseases 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tinidazole

Trials by Country

Trials by Country for Tinidazole
Location Trials
United States 10
Taiwan 7
China 3
United Kingdom 2
Brazil 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tinidazole
Location Trials
Texas 2
Alabama 2
North Carolina 2
Pennsylvania 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tinidazole

Clinical Trial Phase

Clinical Trial Phase for Tinidazole
Clinical Trial Phase Trials
Phase 4 19
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tinidazole
Clinical Trial Phase Trials
Completed 14
Recruiting 10
Not yet recruiting 5
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tinidazole

Sponsor Name

Sponsor Name for Tinidazole
Sponsor Trials
Mackay Memorial Hospital 4
Shandong University 2
Mission Pharmacal 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tinidazole
Sponsor Trials
Other 36
Industry 3
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Johnson and Johnson
Merck
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.